GlassScriptPhysician profile
Irina E Popa
NPI 1649263542
$1,867.42
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,342 · 2020: $207 · 2021: $176 · 2022: $45.33 · 2023: $97.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $67.82 · Gift: $29.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $67.82 |
| Gift | $29.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $257.23 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $172.86 | 2020-2023 | Imbruvica |
| Merck Sharp & Dohme LLC | $132.18 | 2019-2022 | |
| Abbvie INC. | $122.46 | 2019-2021 | |
| Seagen INC. | $122.21 | 2019-2020 | |
| Genentech USA, INC. | $113.13 | 2019 | |
| Novartis Pharmaceuticals Corporation | $97.66 | 2019-2022 | |
| Amgen INC. | $87.35 | 2019 | |
| Lilly USA, LLC | $73.74 | 2019 | |
| Genzyme Corporation | $69.48 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $66.32 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60.09 | 2019 | |
| Janssen Biotech, INC. | $49.21 | 2019 | |
| Array Biopharma INC | $41.94 | 2019-2023 | Mektovi, Lorbrena, Braftovi |
| Pfizer INC. | $38.78 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $37.30 | 2019-2020 | |
| Emd Serono, INC. | $32.42 | 2019 | |
| Celgene Corporation | $30.70 | 2019 | |
| US Oncology Corporate, INC. | $29.42 | 2023 | |
| Foundation Medicine, INC. | $26.31 | 2019 | |
| Rigel Pharmaceuticals, INC. | $21.61 | 2019 | |
| Agios Pharmaceuticals, INC. | $21.09 | 2019 | |
| Amag Pharmaceuticals, INC. | $20.07 | 2019 | |
| Advanced Accelerator Applications | $19.21 | 2019 | |
| Tersera Therapeutics LLC | $18.97 | 2021 | |
| G1 Therapeutics, INC. | $17.83 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $16.75 | 2019 | |
| Partner Therapeutics, INC. | $16.47 | 2019 | |
| Novocure INC. | $15.67 | 2019 | |
| Daiichi Sankyo INC. | $13.92 | 2019 | |
| Astellas Pharma US INC | $13.12 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irina Popa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.